Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

Poliomyelitis Clinical Trial

— IPV-004  

Official title:

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01997632
• Other study ID #: 2013/914
• Secondary ID: 2013-004598-29
• Status: Completed
• Phase: Phase 1
• First received: November 22, 2013
• Last updated: November 9, 2015
• Start date: November 2013
• Est. completion date: May 2014

Study information

• Verified date: November 2015
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate if the study vaccine, m-IPV2 HD (vaccine that only contains polio serotype 2 in high dose), is as safe as the standard IPV Imovax (that contains the 3 serotypes of polio). This safety evaluation will be done in young adults.

If the study vaccine appears to be safe, it will be tested at a later stage in the target group (infants and children) to evaluate the immunogenicity of the vaccine. After all, the purpose is to use the study vaccine in the future to protect young children against Polio serotype 2. Disease with Polio type 2 indeed recently re-appeared, so vaccination of young children to come to a complete eradication of Polio is needed. The standard use of Imovax to protect against Polio serotype 2 would be too expensive. Therefore, a monovalent Polio vaccine containing only serotype 2 (= the vaccine that will be evaluated in this study), has been developed.

The duration of the study will be approximately 6 months. 120 subjects between 18 and 45 years of age will participate in Belgium.

During the study there will be 2 groups of subjects. Subjects will be assigned by chance to one of these groups. One group will receive one single injection of the study vaccine m-IPV2 HD (which contains only serotype 2), the other group will receive one single injection of the standard polio vaccine IPV, Imovax (which contains the 3 serotypes).

After this vaccination, there will be a follow-up period of 6 months. Subjects will be asked to come to the study centre one more time for the second visit (on Day 8, which is 7 days after the first visit). They will also receive 2 follow-up phone calls for approximately one month and 6 months after vaccination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy adults 18-45 years of age

• Subjects born in Belgium or any other country where mandatory polio vaccination is performed.

• Written informed consent obtained from the subject.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

1. has practiced adequate contraception for 30 days prior to vaccination, and

2. has a negative pregnancy test on the day of vaccination, and

3. has agreed to continue adequate contraception for 2 months after vaccination.

Exclusion Criteria:

• Participation in another clinical trial.

• Any polio vaccine within 6 months before study inclusion.

• Any other vaccination in the period starting 14 days before administration of study vaccine and ending 28 days after administration of the study vaccine.

• Previous severe reaction after vaccination with polio vaccine.

• Known hypersensitivity to one or more components of the vaccine.

• Uncontrolled, clinically significant neuro-psychiatric, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic or endocrine disease.

• Subjects with an history of malignant disease (cancer)

• Known human immunodeficiency virus (HIV) positivity or other immune deficiency or immune suppressive treatment or auto-immune disease. For corticosteroids, a prednisone dose of <20 mg/day, or equivalent, is allowed. Inhaled and topical corticosteroids are allowed.

• Acute disease and/or fever (higher or equal to 37.5°C, measured orally) at the time of enrolment. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory tract infection) without fever may be enrolled at the discretion of the investigator.

• Pregnant or lactating female. Subject who, in the opinion of the investigator, is unlikely to comply with the protocol or is inappropriate for any other reason.

• Known hypersensitivity to one or more components of the vaccine.

• Uncontrolled, clinically significant neuro-psychiatric, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic or endocrine disease.

• Subjects with an history of malignant disease (cancer)

• Known human immunodeficiency virus (HIV) positivity or other immune deficiency or immune suppressive treatment or auto-immune disease. For corticosteroids, a prednisone dose of <20 mg/day, or equivalent, is allowed. Inhaled and topical corticosteroids are allowed.

• Acute disease and/or fever (higher or equal to 37.5°C, measured orally) at the time of enrolment. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory tract infection) without fever may be enrolled at the discretion of the investigator.

• Pregnant or lactating female.

• Subject who, in the opinion of the investigator, is unlikely to comply with the protocol or is inappropriate for any other reason.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Poliomyelitis

Intervention

Biological:
• a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)
a single dose m-IPV2 HD (study vaccine), 0,5ml
• a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).
a single 0.5 ml dose Imovax Polio (control vaccine)

Locations

Country	Name	City	State
Belgium	Ghent University Hospital	Ghent	Oost-Vlaanderen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the safety of a single dose of m-IPV2 HD and licensed trivalent IPV	To assess the safety of a single dose of m-IPV2 HD and licensed trivalent IPV in healthy adults based on the incidence of serious and severe adverse events (AEs) within 4 weeks of vaccine administration.	4 weeks	Yes
Primary	the reactogenicity of a single dose of m-IPV2 HD and licensed trivalent IPV	To assess the reactogenicity of a single dose of m-IPV2 HD and licensed trivalent IPV in healthy adults based on the incidence of solicited local and general AEs within 7 days of vaccine administration.	7 days	No
Secondary	the safety of a single dose of m-IPV2 HD and licensed trivalent IPV	To assess the safety of a single dose of m-IPV2 HD and licensed trivalent IPV in healthy adults based on the incidence of serious AEs within 6 months of vaccine administration.	6 months	Yes